Ticker >

Gufic Biosciences share price

Gufic Biosciences Ltd.

NSE: GUFICBIO BSE: 509079 SECTOR: Pharmaceuticals & Drugs  77k   1k   325

282.50
-2.80 (-0.98%)
NSE: 28 Mar 4:00 PM

Price Summary

Today's High

₹ 289.05

Today's Low

₹ 281

52 Week High

₹ 364.9

52 Week Low

₹ 184.2

FinStar

Ownership Below Par
Stock price may face volatility due to ownership structure.
ValuationExpensive
The stock is at a premium valuation at this point.
EfficiencyExcellent
The company knows very well the utilization of its assets.
FinancialsVery Stable
The company possesses stable growth history and manageable debt.
*It is just an analytical rating of the company and not an investment advice.

Company Essentials

Market Cap

2832.84 Cr.

Enterprise Value

3097.56 Cr.

No. of Shares

10.03 Cr.

P/E

33.65

P/B

5.52

Face Value

₹ 1

Div. Yield

0.04 %

Book Value (TTM)

₹  51.15

CASH

46.69 Cr.

DEBT

311.41 Cr.

Promoter Holding

72.51 %

EPS (TTM)

₹  8.4

Sales Growth

-11.36%

ROE

25.84 %

ROCE

23.23%

Profit Growth

-16.84 %

* Total debt includes long term borrowing, short term borrowing plus current maturities of long-term borrowing
* Ratios are based on latest Audited Financial Result.

Your Added Ratios

Please login to Add & View your own added ratios.

Login

Price Chart 1d 1w 1m 3m 6m 1Yr 3Yr 5Yr

 

Volume Chart 1d 1w 1m 3m 6m 1Yr 3Yr 5Yr

* Prices are based on daily market changes.
* The chart is based on the standalone earnings of the company. * Negative values and values more than 1000x in PE chart is considered 0.

Peer Comparison

View Full Peer Comparison
* The Peers list includes companies operating in the same industry and having comparable market cap.

 Group Companies

Track the companies of Group.

Ratios

Sales Growth

1 Year-11.36%
3 Year22.16%
5 Year17.71%

Profit Growth

1 Year-16.84%
3 Year52.02%
5 Year37.06%

ROE%

1 Year25.84%
3 Year32.79%
5 Year30.89%

ROCE %

1 Year23.23%
3 Year33.52%
5 Year30.25%

Debt/Equity

0.8953

Price to Cash Flow

-106.55

Interest Cover Ratio

13.977867765982

CFO/PAT (5 Yr. Avg.)

0.829077869875479

Share Holding Pattern

Promoter Pledging %

Date Promoter % Pledge %
Dec 2023 72.51 0
Sep 2023 75 0
Jun 2023 75 0
Mar 2023 75 0
Dec 2022 75 0
Investors List
* Figures given above are % of equity capital

 Strengths

  • The company has shown a good profit growth of 52.0185989727318% for the Past 3 years.
  • The company has shown a good revenue growth of 22.1597306112717% for the Past 3 years.
  • Company has been maintaining healthy ROE of 32.7901963168149% over the past 3 years.
  • Company has been maintaining healthy ROCE of 33.5228025692982% over the past 3 years.
  • Company has a healthy Interest coverage ratio of 13.977867765982.
  • The company has an efficient Cash Conversion Cycle of -18.0169576172054 days.
  • The company has a high promoter holding of 72.51%.

 Limitations

  • Company has negative cash flow from operations of -26.5872.

Quarterly Result (All Figures in Cr.)

PARTICULARS Dec 2022 Mar 2023 Jun 2023 Sep 2023 Dec 2023
Net Sales 177.47 173.04 195.02 214.87 201.78
Total Expenditure 144.08 140.89 159.54 175.5 165.32
Operating Profit 33.39 32.15 35.48 39.37 36.46
Other Income 0.76 0.62 0.88 0.33 0.42
Interest 2.16 2.92 4.07 4.46 3.18
Depreciation 4.74 5.92 4.24 4.3 4.14
Exceptional Items 0 0 0 0 0
Profit Before Tax 27.25 23.93 28.05 30.95 29.56
Tax 6.91 5.83 7.43 7.74 7.3
Profit After Tax 20.34 18.11 20.62 23.21 22.26
Adjusted EPS (Rs) 2.1 1.87 2.13 2.39 2.22

Profit & Loss (All Figures in Cr. Adjusted EPS in Rs.)

PARTICULARS Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023
Net Sales 350.77 378.84 487.7 779.16 690.62
Total Expenditure 304.78 326.72 403.78 631.13 555.97
Operating Profit 45.98 52.12 83.92 148.03 134.65
Other Income 4.17 5.79 3.73 3.1 2.57
Interest 10.16 13.91 13.63 5.37 8.22
Depreciation 4.65 13.86 16.31 18.93 22.28
Exceptional Items 0 0 0 0 0
Profit Before Tax 35.35 30.13 57.71 126.84 106.72
Tax 13.41 7.44 13.48 31 27.02
Net Profit 21.94 22.69 44.23 95.84 79.7
Adjusted EPS (Rs.) 2.82 2.34 4.56 9.89 8.22

Balance Sheet (All Figures are in Crores.)

Particulars Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023
Equity and Liabilities
Share Capital 7.78 9.69 9.69 9.69 9.69
Total Reserves 67.56 119.63 163.74 259.42 338.11
Borrowings 11.31 19.54 35.43 47.98 190.68
Other N/C liabilities 5.85 18.24 19.54 17.9 33.5
Current liabilities 217.72 325.6 163.66 186.4 288.21
Total Liabilities 310.23 492.71 392.06 521.4 860.19
Assets
Net Block 24.45 82.58 99.97 115.17 159.57
Capital WIP 9.63 30.61 13.4 40.87 169.59
Intangible WIP 0 0 0 0 0
Investments 0.01 0.01 0.01 0.01 0.78
Loans & Advances 10.16 18.54 17.12 43.65 64.35
Other N/C Assets 2.09 1.84 0.98 0.95 1.8
Current Assets 263.89 359.13 260.58 320.75 464.11
Total Assets 310.23 492.71 392.06 521.4 860.19
* Other Non-current Liabilities include Net deferred Liabilities

Cash Flows (All Figures are in Crores.)

PARTICULARS Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023
Profit from operations 35.35 30.13 57.71 126.84 106.72
Adjustment 13.35 24.63 30.79 23.18 29.64
Changes in Assets & Liabilities -33.52 2.48 8.15 -10.72 -135.25
Tax Paid -9.98 -10.14 -9.4 -33.06 -27.7
Operating Cash Flow 5.21 47.1 87.25 106.24 -26.59
Investing Cash Flow -12.99 -42.53 -6.69 -94.59 -190.73
Financing Cash Flow 7.71 -4.21 -78.62 -6.24 234.31
Net Cash Flow -0.08 0.37 1.94 5.41 16.99

Corporate Actions

Investors Details

PARTICULARS Dec 2022% Mar 2023% Jun 2023% Sep 2023% Dec 2023%
promoters 75.00 75.00 75.00 75.00 72.51
gufic private limited 10.51 10.51 10.51 10.51 10.16
jayesh pannalal choksi - - - - 24.62
pranav jayesh choksi - - - - 7.25
vipula jayesh choksi - - - - 10.01
zircon teconica private l... 21.17 21.17 21.17 21.17 20.47
mr. jayesh pannalal choks... 25.47 25.47 25.47 25.47 -
mr. pranav jayesh choksi 7.50 7.50 7.50 7.50 -
mrs. vipula jayesh choksi... 10.35 10.35 10.35 10.35 -
PARTICULARS Dec 2022% Mar 2023% Jun 2023% Sep 2023% Dec 2023%
investors 25.00 25.00 25.00 25.00 27.49
investor education and pr... - - 0.25 - 0.25
jagdish n master 1.86 1.86 1.85 1.65 1.58
llp 0.86 0.89 0.84 0.76 0.72
motilal oswal financial s... - - - - 3.32
girish gulati huf 1.01 1.01 1.00 1.00 -
investor education and pr... 0.25 0.25 - 0.25 -
sbi healthcare opportunit... 1.03 1.03 1.03 1.03 -

Annual Reports

Ratings & Research Reports

Company Presentations

Company News

Gufic Biosciences - Quaterly Results14 Feb 2024, 5:57PM Gufic Biosciences - Quaterly Results14 Feb 2024, 5:57PM Gufic Biosciences informs about compliance certificate9 Jan 2024, 3:56PM Gufic Biosciences informs about transcript of earnings call 23 Nov 2023, 3:24PM Gufic Biosciences incorporates subsidiary in India20 Nov 2023, 9:58AM Gufic Biosciences - Quaterly Results9 Nov 2023, 5:57PM Gufic Biosciences informs about outcome of board meeting11 Oct 2023, 4:44PM Gufic Biosciences granted patent for invention15 Sep 2023, 10:30AM Gufic Biosciences gets nod for Parecoxib Sodium 40mg injection12 Sep 2023, 10:10AM Gufic Biosciences informs about press release2 Sep 2023, 4:05PM Gufic Biosciences - Quaterly Results11 Aug 2023, 5:27PM Gufic Biosciences - Quaterly Results11 Aug 2023, 5:27PM Gufic Biosciences gets nod from NMPA for PRILOCAINE API17 Jun 2023, 10:33AM Gufic Biosciences informs about press release7 Jun 2023, 4:08PM Gufic Biosciences informs about analyst meet1 Jun 2023, 2:39PM Gufic Biosciences - Quaterly Results29 May 2023, 6:57PM Gufic Biosciences - Quaterly Results29 May 2023, 6:57PM Gufic Biosciences incorporates wholly owned subsidiary in Ireland4 Mar 2023, 4:31PM Gufic Biosciences informs about incorporation of a wholly owned subsidiary company 4 Mar 2023, 3:54PM Gufic Biosciences - Quaterly Results10 Feb 2023, 6:33PM Gufic Biosciences - Quaterly Results10 Feb 2023, 6:33PM Gufic Biosciences - Quaterly Results11 Nov 2022, 7:30PM Gufic Biosciences - Quaterly Results11 Nov 2022, 7:30PM Gufic Biosciences informs about proceedings of AGM 3 Sep 2022, 3:28PM Gufic Biosciences - Quaterly Results11 Aug 2022, 9:14PM Gufic Biosciences - Quaterly Results11 Aug 2022, 9:14PM Gufic Biosciences targets to capture major share of Rs 3000 crore lyophilized antibacterial market in India7 Jun 2022, 12:29PM Gufic Biosciences’ promoter intends to sell 4.68 lakh shares of his holding2 Jun 2022, 11:06AM Gufic Biosciences informs about press release24 May 2022, 2:16PM Gufic Biosciences - Quaterly Results20 May 2022, 7:16PM Gufic Biosciences - Quaterly Results20 May 2022, 7:16PM Gufic Biosciences to manufacture, sell, distribute Isavuconazonium Sulfate API & finished formulation Isavuconazole11 Apr 2022, 5:43PM Gufic Biosciences informs about press release5 Apr 2022, 5:04PM Gufic Biosciences gets DCGI nod for Thymosin Alpha-15 Apr 2022, 4:48PM Gufic Biosciences informs about analyst meet23 Mar 2022, 11:54AM Gufic Biosciences incorporates wholly owned subsidiary company17 Mar 2022, 11:20AM Gufic Biosciences enters into research and collaboration agreement with Selvax10 Mar 2022, 9:52AM Gufic Biosciences - Quaterly Results9 Feb 2022, 7:04PM Gufic Biosciences - Quaterly Results9 Feb 2022, 7:04PM Gufic Biosciences informs about newspaper publication21 Dec 2021, 4:58PM Gufic Biosciences - Quaterly Results3 Nov 2021, 6:28PM Gufic Biosciences informs about book closure31 Aug 2021, 12:44PM Gufic Biosciences informs about newspaper publication28 Aug 2021, 2:50PM Gufic Biosciences informs about written transcript of earnings call 17 Aug 2021, 3:43PM Gufic Biosciences informs about disclosure10 Jun 2021, 4:43PM Gufic Biosciences informs about earnings call9 Jun 2021, 11:15AM Gufic Biosciences informs about outcome of board meeting5 Jun 2021, 11:22AM Gufic Biosciences gets permission to manufacture, market Liposomal Amphotericin B Injection21 May 2021, 11:14AM Gufic Biosciences informs about clarification on price movements18 May 2021, 3:49PM Gufic Biosciences informs about credit rating6 Mar 2021, 12:06PM

Gufic Biosciences Stock Price Analysis and Quick Research Report. Is Gufic Biosciences an attractive stock to invest in?

 

The Indian healthcare sector is expected to reach US$ 372 billion by 2022, driven by rising incomes, greater health awareness, lifestyle diseases and increasing access to insurance. Healthcare has become one of India’s largest sectors - both in terms of revenue and employment.

Healthcare comprises hospitals, medical devices, clinical trials, outsourcing, telemedicine, medical tourism, health insurance, and medical equipment. The structure of the healthcare delivery system in India consists of three broad segments: Primary care, Secondary care, and Tertiary care.

  • Primary care is the first point of contact between the population and the healthcare service providers. For example, Sub-center (SC), Primary Health Centre (PHC) and Community Health Centre (CHC) which is more relevant to rural areas (PHC’s).
  • Secondary care providers inpatient as well as outpatient medical services and includes simple surgical procedures. For example, District level & Mid-sized hospitals.
  • Tertiary care is the third level of the healthcare delivery system in the country. These hospitals are specialized consultative healthcare infrastructure. For example, Single specialty and Multi-specialty hospitals.

While healthcare services are offered by the public as well as private sectors, in urban as well as rural areas, generally people prefer private hospitals over public hospitals for treatment of diseases, illness, and sickness. So, let’s look into Gufic Biosciences and its performance over the period of time.

  • Operating cash flow ratio: It measures the adequacy of a company’s cash generated from operating activities to pay off short-term financial obligations. Gufic Biosciences cash from the operating activity was Rs -26.5872 Cr.
     
  • Financial Strength: Health care organizations usually have high debt loads and low equity capital in their balance sheet. So, Debt to Equity ratio is important to analyze the company’s sustainability. Gufic Biosciences has a Debt to Equity ratio of 0.8953 , which is a strong indication for the company.
     
  • EPS growth: Investors should ensure the EPS figure is growing faster than revenue numbers because it indicates company management is increasing the efficiency with which it runs the company. In Gufic Biosciences , the EPS growth was -16.8349180659518 % which is bad for the company.
     
  • Operating profit margin: It determines a company's potential earnings. It assesses how well-managed a company with respect to its basic overhead costs and other operating expenses, Gufic Biosciences has OPM of 19.4971393853183 % which is a good sign for profitability.
     
  • ROE: Gufic Biosciences have a healthy ROE of 25.8393305390499 %. ROE is an important financial parameter for hospitals & health care companies because they expand and grow rapidly. Therefore, ROE measures how efficiently a shareholder's fund is used for generating profits.
     
  • Share Price: - The current share price of Gufic Biosciences is Rs 282.5. One can use valuation calculators of ticker to know if Gufic Biosciences share price is undervalued or overvalued.
Last Updated on:
Brief about Gufic Biosciences

Gufic Biosciences Ltd. Financials: Check Share Price, Balance Sheet, Annual Report, Quarterly Results, Shareholding, Company Profile and News for Company Analysis

Gufic Biosciences Ltd. is a leading pharmaceutical company that specializes in the development, manufacturing, and marketing of a wide range of healthcare products. With a strong presence in both domestic and international markets, Gufic Biosciences is recognized for its high-quality offerings and its commitment to innovative healthcare solutions.

Established in [year], Gufic Biosciences has emerged as a trusted name in the pharmaceutical industry. The company operates across various therapeutic segments, including pain management, diabetes care, cardiology, dermatology, and more. Gufic Biosciences' products are manufactured at state-of-the-art facilities that adhere to international quality standards.

Share Price Analysis - Gufic Biosciences Ltd.

The share price of Gufic Biosciences Ltd. reflects the market perception and investors' confidence in the company's growth potential. Investors can track the share price through various platforms, including our website, where we provide real-time stock prices and historical data.

Our pre-built screening tools allow investors to analyze and compare the share price of Gufic Biosciences against industry peers, helping them make informed investment decisions. These tools provide insights into historical trends, price movements, and market performance.

Balance Sheet Analysis - Gufic Biosciences Ltd.

The balance sheet of Gufic Biosciences Ltd. provides a snapshot of the company's financial position at a given point in time. It reflects the assets, liabilities, and shareholders' equity of the company. Investors can access the company's balance sheet on our website, where we provide downloadable annual reports.

For long-term investors looking for stock analysis, our premium features offer fair value calculation using tools such as DCF Analysis, BVPS Analysis, Earnings multiple approach, and DuPont analysis. These tools can help investors assess the financial health and intrinsic value of Gufic Biosciences.

Annual Report Analysis - Gufic Biosciences Ltd.

The annual report of Gufic Biosciences is a comprehensive document that provides detailed information about the company's operations, financial performance, and future outlook. It contains key financial statements, management discussions, and analysis of risks and opportunities.

As a long-term investor, it is crucial to review the annual report to gain insights into the company's strategy, competitive positioning, and growth prospects. At our website, we provide downloadable annual reports of Gufic Biosciences, allowing investors to analyze the company's performance in detail.

Dividend Analysis - Gufic Biosciences Ltd.

Dividends play an essential role in long-term investments, as they reflect the company's ability to generate profits and return value to shareholders. Gufic Biosciences has a track record of consistently rewarding its shareholders through dividends.

Investors can assess the dividend history and dividend yield of Gufic Biosciences using our pre-built screening tools. These tools provide an overview of the company's dividend payouts, helping investors make informed decisions based on their income requirements and investment objectives.

Quarterly Result Analysis - Gufic Biosciences Ltd.

The quarterly results of Gufic Biosciences provide an update on the company's financial performance and its ability to meet its targets. Investors can access the quarterly results on our website, where we provide downloadable financial statements and reports.

Our premium features enable investors to perform in-depth analysis of the quarterly results using tools such as DCF Analysis, BVPS Analysis, Earnings multiple approach, and DuPont analysis. These tools assist investors in understanding the key drivers behind the company's financial performance and its future growth prospects.

Stock Price Analysis - Gufic Biosciences Ltd.

The stock price of Gufic Biosciences is influenced by various factors, including market dynamics, industry trends, company performance, and investor sentiment. Investors can track the stock price through our website, where we provide real-time data and detailed price charts.

Additionally, our pre-built screening tools allow investors to analyze and compare the stock price of Gufic Biosciences against industry peers. These tools provide insights into historical trends, price movements, and market performance, aiding investors in their decision-making process.

News Analysis - Gufic Biosciences Ltd.

Keeping up with the latest news and updates about Gufic Biosciences is essential for long-term investors. Our website provides a dedicated news section where investors can access the latest announcements, press releases, and industry updates related to Gufic Biosciences.

Staying informed about the company's developments, product launches, collaborations, and regulatory updates can help investors make well-informed investment decisions. Our website serves as a reliable source of news and information for investors interested in Gufic Biosciences.

Concall Transcripts Analysis - Gufic Biosciences Ltd.

The concall transcripts of Gufic Biosciences provide valuable insights into the company's performance, strategy, and future outlook. Investors can access the concall transcripts on our website, where we provide downloadable transcripts of the company's earnings calls.

Reviewing the concall transcripts helps investors understand management's perspective and their plans to drive future growth. These transcripts serve as a valuable resource for long-term investors seeking a deeper understanding of Gufic Biosciences' business operations.

Investor Presentations Analysis - Gufic Biosciences Ltd.

Gufic Biosciences regularly conducts investor presentations to showcase its achievements, growth plans, and future prospects. These presentations provide detailed information about the company's business model, product portfolio, and market opportunities.

Investors can access these investor presentations on our website, where we provide downloadable copies. Reviewing these presentations can help investors gain valuable insights into Gufic Biosciences' strategic initiatives, competitive advantages, and potential investment opportunities.

Promoters and Shareholders Analysis - Gufic Biosciences Ltd.

Gufic Biosciences has a strong base of promoters and shareholders who have played a vital role in the company's success. Understanding the key stakeholders and their holdings can provide insights into the confidence placed in Gufic Biosciences by industry experts and institutional investors.

While we do not provide specific details of individual promoters and shareholders, our website offers resources that help investors understand the ownership structure and the influence of key stakeholders on Gufic Biosciences' decision-making processes.

In conclusion, Gufic Biosciences Ltd. is a reputable pharmaceutical company that offers innovative healthcare products. Investors interested in long-term stock analysis can utilize our website for comprehensive insights into the company's profile, share price, balance sheet, annual reports, dividend history, quarterly results, stock price, news updates, concall transcripts, investor presentations, and key stakeholders. Our pre-built screening tools and premium features enable investors to perform in-depth analysis and fair value calculations, assisting in informed investment decision-making.

Read More
X